Background The effects of empagliflozin in patients with chronic kidney disease who are at
risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed …

Background Diabetes confers an increased risk of adverse cardiovascular and renal events.
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 …

Background: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced
cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and …

Summary Background The EMPA-KIDNEY trial showed that empagliflozin reduced the risk
of the primary composite outcome of kidney disease progression or cardiovascular death in …

Background: In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial
in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of …

OBJECTIVE To assess the safety of empagliflozin in patients with type 2 diabetes and
moderate to severe chronic kidney disease (CKD)(category G3–4) enrolled in clinical trials …

Background Diabetes is a leading cause of chronic kidney disease (CKD) worldwide.
Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk …

Abstract Aims/Introduction In the EMPA‐REG OUTCOME® trial, empagliflozin added to
standard of care improved clinically relevant kidney outcomes by 39%, slowed progression …

Background Empagliflozin slowed the progression of CKD in patients with type 2 diabetes
and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical …

Abstract Aims In the EMPA‐REG OUTCOME® trial, the sodium‐glucose cotransporter 2
inhibitor empagliflozin when given in addition to standard care improved cardiovascular …